Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China

Abstract

Background: Representative prognostic data by clinical characteristics for lung cancer is not yet available in China. This study aimed to calculate the survival of lung cancer patients with different pathological evaluations, explore their predictive effects and provide information for prognosis improvement. Methods:In this multicenter cohort study, primary lung cancer patients diagnosed in 17 hospitals at three distinct levels in China between 2011-2013 were enrolled and followed up till 2020. Overall survival and lung cancer specific survival were calculated by Kaplan-Meier method. Cox proportional hazards model was applied to assess the effects of predictors of lung cancer survival.Results: Of all the 7,311 patients, the 5-year overall and lung cancer specific survival rates were 37.0% and 41.6%, respectively. For lung cancer patients at stages I, II, III, and IV, the 5-year overall survival rates were 76.9%, 56.1%, 32.6%, and 21.4%, respectively; the lung cancer specific survival rates were 82.3%, 59.7%, 37.2%, and 26.4%, respectively. Differences of survival for each stage remained significant between histological classifications (P<0.01). The 5-year overall survival rates for patients with squamous cell carcinoma, adenocarcinoma (AC), and small cell carcinoma were 36.9%, 43.3% and 27.9%, respectively; the corresponding disease-specific rates were 41.5%, 48.6% and 31.0%, respectively. Such differences were nonstatistically significant at advanced stages (P=0.09). After multivariate adjustments, stage and classification remained independent predictors for the survival of lung cancer. Conclusions:The prognosis of lung cancer varied with the pathological stages and histological classifications, and had room for improvement. Stage was the strongest predictor, so efforts on early detection and treatment are needed.

Both In Situ and Circulating SLC3A2 Could Be Used as Prognostic Markers for Human Lung Squamous Cell Carcinoma and Lung Adenocarcinoma

“…Lung cancer has a high incidence and mortality worldwide [ 7 ]. The pathogenesis of lung cancer has not been fully understood, but there is evidence that the occurrence of lung cancer is related to smoking, air pollution, occupational carcinogens, diet, genetics, and other factors [ 8 , 9 , 10 ]. Most patients with lung cancer are in an advanced stage when they go to hospital [ 11 ].…”

The Smokers Health Multiple ACtions (SMAC-1) Trial: Study Design and Results of the Baseline Round

“…Tobacco use is the single greatest preventable cause of disease and premature death worldwide. At the time of diagnosis, lung cancer is often already at an advanced stage, with a 5-year survival of 15% or less [54][55][56][57].…”

LncRNA RP11-58O9.2 predicts poor prognosis and promotes progression of non-small cell lung cancer

“…LC has high morbidity and mortality rates worldwide, and despite new therapeutic measures, the 5-year survival rate of patients with advanced LC in China was still only approximately 16% in 2022. [15][16][17][18][19] OS and LC-specific survival rates also decrease significantly with increasing LC stage, indicating that the stage at initial diagnosis is a crucial factor affecting LC prognosis. 20,21 The development of molecularly targeted agents and immune checkpoint inhibitors has provided better treatment options for patients with NSCLC; however, drug resistance represents a new challenge for cancer therapy.…”